Abstract
Background Most differentiated service delivery (DSD) models for HIV treatment, which are intended to improve ART programme outcomes, require that a patient have spent ≥6 or ≥12 months on antiretroviral treatment (ART) ART for eligibility. Attrition from ART programmes, however, is highest among those newly initiated and thus ineligible for DSD models. Because some patients are enrolled “early,” prior to 6 or 12 months on ART, we were able to evaluate loss to follow-up among patients in Zambia enrolled in DSD models after differing intervals on ART.
Methods Data were extracted from electronic medical records of patients (≥15 years) enrolled in DSD models from October 2019-March 2020. We compared 12-month loss to follow-up (LTFU), defined as “lost to follow-up,” “inactive,” or “stopped ART” at 9-15 months after DSD enrolment, among patients enrolled in six DSD models after <6 months, 6-12 months, and ≥ 12 months on ART, with those enrolled with <6 or <12 months on ART termed “early enrollers and those enrolled with ≥12 months termed “established.” We adjusted for age, sex, urban/rural status, and duration of ART dispensing.
Results Of 88,556 patients enrolled in a DSD model, 4% (n=3,143) and 8% (n=6,714) had initiated ART <6 months or 6-12 months before DSD entry, respectively. Early enrollers were less likely to be LTFU at 12 months than established patients (adjusted risk ratio (aRR) [95% confidence interval] for <6 months on ART 0.72 [0.62-0.83]; aRR 0.74 [0.67-0.82] for 6-12 months on ART) for almost all DSD models and dispensing durations. A limitation of the analysis is that early enrollers may have been selected for DSD participation due to providers’ expectations about future retention.
Conclusions Patients enrolled in DSD models in Zambia after less than a year on ART were more likely to be retained in care 12 months later than were patients established on ART at DSD enrollment. Offering enrollment to at least some newly-initiating ART patients may improve ART programme outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for the study was provided by the Bill & Melinda Gates Foundation through OPP1192640 to Boston University. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study protocol was approved by ERES Converge IRB (Zambia), protocol number 2019-Sep-030, the Human Research Ethics Committee (Medical) of the University of Witwatersrand, protocol number M190453, and the Boston University IRB, protocol number H-38823.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data were obtained from Zambia's national electronic medical record system. Derived data supporting the findings of this study are available from the corresponding author [BEN] on request.
